Johnson & Johnson’s
JNJ,
experimental HIV vaccine is safe but not effective, and the late-stage study will be discontinued as a result of that finding, federal researchers said Wednesday. J&J’s stock was down 1.1% in trading on Wednesday afternoon. The vaccine was being tested in a Phase 3 clinical trial that enrolled 3,900 men who have sex with men and transgender people in several countries, including the U.S. The National Institute of Allergy and Infectious Diseases provided funding for the trial. J&J’s stock is up 1.9% over the past year, while the S&P 500
SPX,
has declined 14.4%.
